Page 1

July 27 , 2021 Relmada Therapeutics Announces Top- Line Results of Study Evaluating REL - 1017 vs Oxycodone for Abuse Potential - All tested doses of REL - 1017 , including the maximum tolerated dose , showed a highly statistically significant difference in abuse potential vs. oxycodone with p - values < 0.001 - Company to host conference call at 8:30 AM Eastern Time today July 27 , 2021 NEW YORK , July 27 , 2021 / PRNewswire / -- Relmada Therapeutics , Inc. ( Nasdaq : RLMD ) , a late - stage biotechnology company addressing diseases of the central nervous system ( CNS ) , announced today top - line results of the human abuse potential ( HAP ) study with REL - 1017 , a novel NMDA receptor ( NMDAR ) channel blocker and the company's lead candidate in Phase 3 development for the treatment major depressive disorder ( MDD ) . B Relmada THERAPEUTICS Top - line results showed that all three doses of REL - 1017 ( 25 mg , 75 mg and 150 mg , the therapeutic , supratherapeutic and maximum tolerated doses , respectively ) tested in recreational opioid users , demonstrated a highly statistically significant difference vs. the active control drug , oxycodone 40 mg . The study's primary endpoint was a measure of " likability " with the subjects rating the maximum effect ( or Emax ) for Drug Liking " at the moment " , using a 1 = 100 bipolar rating scale ( known as a visual analog scale or VAS ) , with 100 as the highest likability , 50 as neutral ( placebo - like ) , and 0 the highest dislike . Results are summarized in the table below . Mean Emax for Drug Liking Placebo 51.7 P - value for Difference vs. oxycodone 40 mg < 0.001 REL - 1017 25 mg 53.0 < 0.001 REL - 1017 75 mg 58.2 < 0.001 REL - 1017 150 mg 64.9 Oxycodone 40 mg 85.0 < 0.001 " These highly statistically significant data clearly demonstrate a very meaningful difference between REL - 1017 and oxycodone at all three tested doses " said Sergio Traversa , CEO of Relmada Therapeutics . " These results , along with previously published literature , confirm the lack of opioid effects of REL - 1017 . We look forward to the continued clinical development of REL - 1017 as a novel , safe and rapidly effective treatment for MDD . " " We are pleased with the results of this confirmatory study , which was designed in line with